Hims & Hers Health, Inc. (HIMS) Latest Filing Signal

Latest Filing: 10-K  |  Filed Feb 23, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Hims & Hers Health, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Hims & Hers Health, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+34.36%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Turned Positive
CLAUDE
Turned Negative
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Hims & Hers Health, Inc. actually do?
Answer:
Hims & Hers Health, Inc. operates a consumer-first digital platform that provides telehealth consultations and access to prescription and non-prescription health and wellness products. The company focuses on chronic conditions such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, offering personalized treatment plans fulfilled through online pharmacies. Expanding its reach, Hims & Hers operates in the United States, Canada, the United Kingdom, and parts of the European Union, with plans for further international growth. Its business model is largely subscription-based, providing recurring revenue and customer predictability, supported by a technology-driven platform designed for efficient scaling and the addition of new services.
Question:
What are Hims & Hers Health, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by subscription-based sales of prescription and non-prescription health and wellness products and services purchased directly by consumers through the company's online platform. Wholesale revenue from non-prescription product sales to retailers also contributes to overall revenue.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required